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SUMMARY
The statistical literature on assessing the accuracy of risk factors or disease markers as diagnostic tests deals
almost exclusively with settings where the test,
 
, is measured concurrently with disease status  . In prac-
tice, however, disease status may vary over time and there is often a time lag between when the marker is
measured and the occurrence of disease. One example concerns the Framingham Risk Score as a marker for
the future risk of cardiovascular events, events that occur after the score is ascertained. To evaluate such a
marker, one needs to take the time lag into account since the predictive accuracy may be higher when the
marker is measured closer to the time of disease occurrence. We therefore consider inference for sensitivity
and specificity functions that are defined as functions of time. Semi-parametric regression models are pro-
posed. Data from a cohort study are used to estimate model parameters. One issue that arises in practice is
that event times may be censored. In this research, we extend in several respects the work by Leisenring, Pepe
and Longton (1997) that dealt only with parametric models for binary tests and uncensored data. We pro-
pose semi-parametric models that accommodate continuous tests and censoring. Asymptotic distribution
theory for parameter estimates is developed and procedures for making statistical inference are evaluated
with simulation studies. We illustrate our methods with data from the Cardiovascular Health Study, relating
the Framingham risk score measured at enrollment to subsequent risk of cardiovascular events.
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1 INTRODUCTION
The use of clinical and laboratory data to predict future patient events is a very popular idea in
medicine at present. Biomarkers are under development to detect cancer before onset of clinical dis-
ease (Pepe et al, 2001). Gene expression profiles of tumor tissue promise to be predictive of survival
in cancer patients (Veer et al, 2002). Clinical scores, such as the Framingham Risk Score (Wilson et al,
1998), are considered predictive of myocardial infarction and stroke. It is critical to evaluate the sensi-
tivity and specificity of such predictors or markers before adopting them for use in clinical practice.
The literature on evaluating the accuracy of a marker, predictor or diagnostic test result,   , deals
primarily with settings where   is measured concurrently with the gold standard disease variable  .
The True Positive Rate (TPR) and False Positive Rate (FPR) functions are:
TPR  pr  
	 FPR  pr  
	
where ﬀ indicates disease present,  denotes its absence and the threshold  is used to define
a positive test result as  ﬁ	ﬂ . If   is continuous, an ROC curve that plots TPR  versus FPR  for
all possible values of  is often used to describe the discriminatory capacity of   .
The notions of true and false positive rates must be extended when the outcome is an event time
random variable ﬃ and the time at which   is measured relative to ﬃ can vary. Indeed, the timing of
the measurement, denoted by  , is likely to impact on the capacity of   !" to predict ﬃ . Measurements
made closer to the event time are likely to be more predictive. We define the time dependent TPR
function:
TPR #%$ &'( pr )*  !"+	*ﬃ-,./1032+ (1 4 1)
where the time lag is 0 . For a subject that has an event at ﬃ , TPR #%$ & ( is the probability of test positive
with the marker at 0 time units prior to the event. Typically the TPR function will be a monotone
decreasing function of 0 . The FPR, or 1 - specificity, relates to subjects without events, or at least event
free by some suitably large time 5 after the marker is measured. Therefore we define
FPR 6
$ &
( pr )7  !"8	9ﬃ-,.;:5<2= (1 4 2)
These definitions are consistent with those used by Balasubramanian and Lagakos (2001), Leisenring,
Pepe and Longton (1997) and Etzioni et al (1999) and are commonly used in practice. In breast cancer
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screening research for example, 5 

years is typically used. The rationale is that it can be assumed
that if clinical disease does not emerge by 2 years after screening, the subject was free of subclinical
disease at the time of screening. Heagerty, Pepe and Lumley (2000) define cumulative incidence based
TPR and FPR functions:
TPRCI
#%$ &
( pr )*  ! +	 97ﬃ1,  0 28 (1 4 3)
FPRCI
#%$ & $
( pr )*  ! +	 97ﬃ1,  : 0 2 (1 4 4)
However, the definitions in (1 4 1) and (1 4 2) lead to more straightforward regression modeling proce-
dures and are easier to interpret as functions of time than their cumulative incidence based counter-
parts. For extensive discussion see Pepe (2003, pages 259–65). Moreover, we can calculate (1 4 3) and
(1 4 4) from (1 4 1) and (1 4 2) with knowledge of the event time distribution. Thus we concentrate on (1 4 1)
and (1 4 2) here initially, and return to (1 4 3) and (1 4 4) in the example.
In this paper we consider models for the time dependent  TPR  FPR  functions in (1 4 1) and (1 4 2)
and procedures to make inference about them from prospective cohort studies. The marker   may
be measured at multiple times for a subject, covariates  that affect the true and false positive rates
may be available and the event time ﬃ can be right censored. We extend the marginal regression
modeling approach of Leisenring, Pepe and Longton (1997) which deals only with binary markers  
and uncensored failure times. We develop our method in a simplified setting in the next section. The
more general setting is discussed in section 3. Results from simulation studies described in section 4
suggest that the procedures work well in finite samples when the assumptions hold. In the second
part of section 4 we apply the methods to data from the Cardiovascular Health Study, a prospective
cohort study of older adults (Fried et al, 1991). We investigate the sensitivity (TPR) and specificity
(1-FPR) of the Framingham risk score as a marker for future cardiovascular events in this population.
As expected, we show that the score is better at discriminating short term than long term risk and that
it works better in females than in males. However, the score is not a very accurate predictor in any
subgroup studied. We close in section 5 with a discussion of alternative approaches to the evaluation
of markers for event time data.
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2 MODELLING AND ESTIMATION IN A SIMPLE SETTING
We only consider marker measurements made prior to the event time,   !" for   ﬃ . The event time
can be right censored by a censoring variable

that is independent of ﬃ conditional on the covariates.
Define the observation time    ﬃ 

 and 	 
( ﬃ 

 . First, we consider the simple scenario
with   binary and measured at baseline, / , for each person. The data for analysis are
)      	     2 
where   is the . covariate vector. We assume the following models for the true and false positive
rates:
TPR
#%$ ﬀ
 pr   ;*ﬃﬁ 0   ﬃﬂ D
! #"" "%$
%0 ﬁ&('' '*)+ ,&ﬃ-
+!.
 for 0  5  (2 4 1)
FPR 6
$ ﬀ
 pr    ;7ﬃﬁ:5   ﬃﬂﬀ/D
!0
)+
12&43
+
.
 (2 4 2)
where ﬂ D and ﬂ /D are specified inverse link functions. The dependence of the TPR on time is through the
parametric function
 5" " "$
%0  
" " "
)
+
   
%03 , where
   
is a vector of polynomials or spline basis functions. The
false positive rate is not a function of time. The TPR and FPR rates (2 4 1) and (2 4 2) are mathematically
distinct functions. Separate modeling of TPR and FPR is often undertaken in practice because the
behavior of the marker may be very different in cases than in controls. See Carney et al (2003) for an
example. However, it is also possible to specify (2 4 1) and (2 4 2) with shared parameters. Alternatively,
one may assume that (2 4 1) holds for all 0 and drop (2 4 2) completely. Then the covariate specific FPR can
be derived from (2 4 1) with FPR 6 $ ﬀ  ,768
6
TPR #%$ ﬀ:9ﬀ;<ﬀ %0 >= ;<ﬀ 5< , where ;* %0  is the covariate specific
survivor function for ﬃ . However, typically censoring does not allow estimation of TPR over  @?- so
it is more appealing to assume (2 4 1) for 0BAﬂ5 and to supplement it with the FPR model (2 4 2). This is
analogous to the approach taken by Hogan and Laird (1997) in the mixture model framework where
they reserved a multinomial category for subjects who have not yet experienced an event by the end
of the study.
Denote all the parameters in (2 4 1) and (2 4 2) by C C CD+ . Note that (2 4 1) models the distribution of   
conditional on )'ﬃ<  1 2 when ﬃﬁ 5 and (2 4 2) models the distribution of  < conditional on )'ﬃ< :5   2 .
The likelihood of the data is therefore
E
F
G*H
)I :CC CJ+ 2LK

) ,MI :CC CJ+7 2
HON
K

 (2 4 3)
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where the conditional probability < :C C C +  is
TPR   %$ ﬀ if   5 	 
,
6
6
  
TPR
#%$ ﬀ 9 ;*ﬀ %03ﬁ&
FPR 6 $ ﬀ ;<ﬀ 5<
;<ﬀ   
if   5 	  
FPR 6 $ ﬀ if  : 5 
(2 4 4)
and ;* %0  pr  ﬃ: 0    . We can think of the first and third groups as cases and controls, respectively,
while the case/control status of the second group, i.e. those censored in

 5 , are unknown.
A consistent estimator of C C C + can be obtained by using only data from subjects in the first and third
groups. This is the approach taken by Leisenring et al. (1997). To incorporate observations from
subjects who are censored before 5 , one needs to estimate ;  4  since the likelihood contributions from
these subjects involve ;   4  . To this end, we assume a proportional hazards model for ﬃ8  :

%0  



+
%03
	   )+ 

 (2 4 5)
where

%0. 

 is the hazard function for the  th subject and the baseline hazard function

+
%03 is
unspecified. Then
;
ﬀ %0 9 pr  ﬃ 	 0    	 ) , + %0 
	  
)
+


 2 , where  +  4  is the baseline
cumulative hazard function. Under the Cox model (2 4 5), the survival function ;  %03 can be consistently
estimated as

;<
%0 
	 ) ,
+
%0 	 

  
)
  2"
where

   is the maximum partial likelihood estimator based on )   	           2 , and  + %0  is
the Breslow estimate of the cumulative baseline hazard function  + %0  (Fleming and Harrington, 1991).
Plugging in the estimated survival function to (2 4 4), we obtain approximate conditional probabilities,

I :CC C  . Then C C C + can be estimated by maximizing the approximated likelihood function, or equivalently,
as the solution to the approximated score equation,
E

G*H


ﬁﬀ
C C Cﬃﬂ

C C C

I :C C C  )  ,

I :CC C  2
)* 

,



:CC C  2/   (2 4 6)
We note that other regression models for ﬃ can be used. Estimation of C C C + only requires a consistent
estimate of ;  %03 and does not rely on the proportional hazards model assumption.
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3 GENERAL SEMI-PARAMETRIC FRAMEWORK
3 4 1 Model Assumptions
We now generalize to a continuous marker,   , and allow measurements at various times    ,


     , for subject  . To deal with multiple marker measurements, each observation is taken as a unit
and its time origin is reset to    . We model the marginal probability associated with      ﬃ       ,
where     is the marker measured at    and ﬃ   ﬃﬁ ,    is the time lag between the measurement
time and the occurrence of the event. Consider the following marginal probability models:
TPR #%$ &

$ ﬀ ( pr     	*ﬃ   10   3    ﬂ D

 #" " "$
%0 3    &4'''
) +
12& -
+

.
0 5  (3 4 1)
FPR 6 $ &

$ ﬀ
( pr     	7ﬃ   :5   3    ﬂ /D

	 $
!
 
ﬁ&
0
)+
1I&43
+
(
.
 (3 4 2)
where - + and 3 + are baseline functions of the threshold  that are completely unspecified. The TPR
function is allowed to depend on both the time lag ﬃ   and the measurement time    . The FPR func-
tion may only depend on the measurement time. The dependence on time is through the parametric
functions
 !"" "%$
%0 3  
" " "
)
+
   
%0 3" ,
	
$
! 

)
+
	 	 	
!  , where
   
and
	 	 	
are vectors of polynomial or spline basis
functions. In many applications the sensitivity TPR
#%$ &$ 
 4  of the marker depends only on the time lag
0 . However, in some applications the absolute time of the marker measurement may also affect the
TPR functions. Examples include settings where    denotes entry into an intervention study or if
 denotes the subject’s age which is associated with the marker distribution. In the previous section
where    is a constant for all observations (e.g.     ), we set
	
$
!   .
The models written in (2 4 1) and (2 4 2) assume that covariate effects are additive and do not depend
on the thresholding value  . However, one can allow covariate effects to vary with the thresholding
value by including interactions between covariates and parametric functions of  . This is similar to
relaxing the proportional hazards assumption of the Cox model for failure time data by including
interactions between covariate and parametric functions of time. Our estimating procedures apply to
the more general model, but to keep notation simple we work with the simpler model here.
The non-parametric baseline functions of y, - +  4  and 3 +  4  , essentially define the shape and location
of the sensitivity and specificity functions, while the parameters ' ' ' + and
0
+ quantify covariate effects
on them and
 !"" "
$
 4 '4  and
	
$
 4  quantify time effects. Note that, this type of model corresponds to the
marginal semi-parametric transformation model (Dabrowska & Doksum 1988a, 1988b; Cheng, Wei &
6
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Ying 1995, 1997; Scharfstein, Tsiatis & Gilbert 1998; Cai, Wei & Wilcox, 2000). That is, models (3 4 1) and
(3 4 2) can be represented as:
-
+
    ,
   
" " " $
 ﬃ   3    , ' ' ' ) + 
 &  D    if ﬃ   5 
3
+
     ,
	 
$
!    ,
0
) +   & 
/D    if ﬃ   :5 
where pr    D   	 ﬃﬂ D  and pr    /D   	(ﬃﬂﬀ/D ( .
3 4 2 Estimating the Model Components
Let C C CJ+

+
 4 

-
+
 4 3
+
 4 ﬁ
)
 
+


" " "
)
+
'' ' ) +

)
+

0
)
+

)
. denote all the unknown parameters. We base
inference for C C C + on indicator variables 
(    	  since models (3 4 1) and (3 4 2) essentially relate its
conditional expectation      C C CJ+7 to the parameters of interest C C C + . Similar to the binary case, the prob-
ability      C C C  depends on the case/control/censored status of the observation and can be derived
from the models (3 4 1) and (3 4 2) for subjects who have an event before 5 , who are censored before 5 and
who do not have an event before 5 , respectively. To estimate the non-parametric baseline functions,

+
( , we consider the marginal binomial likelihood based on 
  
 
	( and solve the corresponding
score equation
E

G*H



  G*H

	
 


C C C  )L
( 
 
	( ,M
 


C C C  2/  for each 

 " (3 4 3)
where

	
 


C C C  
 



ﬀﬁﬀﬃﬂ
C C Cﬃﬂ


ﬀﬁﬀﬃﬂ
C C Cﬃﬂ 
HON


ﬀﬁﬀﬃﬂ
C C C ﬂ"!
$# is a pre-specified non-negative weight, 	    	 
  ,    
5<%& 
( , 
 
:ﬀ5< and

,  are pre-determined constants such that pr  
 
A

 and pr  
 
:%  are
both positive. To estimate    + , we propose to solve
E

 G*H



  G*H
&('
)

  
 


C C C *
( 
 
	( ,M
 


C C C +
9

,
(  (3 4 4)
where

  
 


C C C  


-
. . .


ﬀﬁﬀﬃﬂ
C C Cﬃﬂ


ﬀ/ﬀ0ﬂ
C C C ﬂ"
HON


ﬀ/ﬀ0ﬂ
C C C ﬂ !


,
 4  is some increasing function that can depend on the data
but converges asymptotically to a deterministic function ,  uniformly in 

1  . The basic idea
then is to solve (3 4 3) and (3 4 4) simultaneously to estimate the parameters in the models (3 4 1) and (3 4 2).
Observe that we now include in the estimating equations a weighting factor # that dictates the
extent to which the censored observations in

 5 enters into the analysis (we have # HON32    for
known cases and controls because  , 	    for them). If # is set to 0, then censored observations
7
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are excluded entirely from the analysis which corresponds to the Leisenring et al (1997) approach. The
score equation given in (2 4 6) for the binary case essentially sets # to 1. Increasing # allows censored
observations to have more influence on estimation. A variety of values for # are investigated later in
simulation studies. Again, when #9: , an estimate of the survivor function ; ﬀ  4  is required in order
to approximate the probabilities      C C C  for censored observations. In summary, we propose a two
step approach to estimating C C C + :
(1) Estimation of C C CJ+ when #  .
Let  C C C  *
 

 4      + denote the solution to the estimating equations (3 4 3) and (3 4 4) when # ﬁ , i.e.
when the censored observations with   ,    5 and 	   are ignored. )
" " "
+
'' ' + @-
+
 4  2 are estimated
using only the cases, observations with  *, 
 
5 and 	  , and )

+

0
+
3
+
 4  2 are estimated using
only the controls, i.e. observations with   , 
 
:15 . We show in Appendix A that  C C C is a consistent
estimator of C C C + for 

   .
(2) Estimation of C C CJ+ when # : .
To include observations with 	
 
  in estimating C C C + , we set # :
 and approximate 
 


C C C  for
those censored subjects by using the estimated survivor function
; 
 4  as in the binary case assum-
ing a proportional hazards model (2 4 5). Then we solve (3 4 3) and (3 4 4) using the weight functions

	
 


C C C  and

  
 


C C C  evaluated at  C C C . Let

C C C  )

-  4 

3" 4 

   2 denote the final estimator for C C C + .
3 4 3 Inference in Large Samples
We show in appendix A that

C C C is unique for large  and is consistent. Furthermore, 




   ,   
+
 is
asymptotically equivalent to  N


N H
E
G*H

E

G*H
	

 , where  and
	

 are defined in appendix A and
B, respectively. It follows from properties of U-statistics (Serfling, 1980) that 




  (,   
+
 is approximately
normal with mean  and variance     N
E
G*H

E

G*H

E
 G*H
$
 G


	


&
	

 3
	
 
&
	
  

)
 Now, let

 and

   be the matrices obtained by replacing all the theoretical quantities in  and    with their empirical
counterparts. Then, the covariance matrix of 




   ,   
+
 can be approximated by


N H

  


N H .
We now turn to inference about the TPR and FPR functions, which depend on time and on covari-
ates  . Substituting )

   

- 

3 ( 2 into (3 4 1) and (3 4 2), we propose estimating TPR
#%$ &$ 
( and FPR 6
$ & $ 
(
8
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as:
 
TPR #%$ &$  (ﬃﬂ D *
 

" " "
%0 3"ﬁ&

' ' '
)
 &

- (+.
 
FPR 6 $ &$    ﬂ /D *
	


!" &

0
)  &

3+ 
To obtain pointwise and simultaneous confidence intervals for the TPR and FPR functions, we show in
appendix B that the process

  0 3   



ﬂ
N H
D )
 
TPR #%$ &$  ( 2/, ﬂ N HD ) TPR #%$ &$   2">ﬂ
N H
/D )
 
FPR 6 $ &$   2 ,
ﬂ
N H
/D ) FPR 6 $ & $  ( 2  ) is asymptotically equivalent to

N


E

G*H
E


G*H

	


 &

   
%0 3 
)

)
 
 
	 	 	
! 
)

)


N H
	




where



 is defined in (B.1). This allows us to approximate the distribution of the process

  0 3"  
using re-sampling techniques (Parzen, Wei and Ying, 1994) in practice. This technique avoids the need
to derive explicit analytic expressions for variance-covariance processes, which seem intractable in our
setting. Moreover, relative to other re-sampling methods such as the bootstrap, the computational bur-
den is minimal. A detailed description of the procedure for constructing confidence bands based on
the re-sampling method can be found in Cai & Pepe (2002).
4 SIMULATION STUDIES AND EXAMPLE
4 4 1 Simulation Studies
Simulation studies were performed to examine the finite sample properties of the estimation proce-
dures proposed in the previous sections and to investigate the impact of # on their efficiencies. The
results suggest that our methods provides reasonably unbiased estimates of both the model parame-
ters and  TPR  FPR  functions. The choice of # affects the efficiency of all parameters of interest, but
seems to have most impact on

0
, less on

' and very little on

"
in the settings we considered. Recall that
when #   , censored observations are ignored for estimation. By including censored observations,
i.e. using # :1 , we find that the estimates are almost always more precise than those calculated with
#   . See Cai et al (2003) for details on simulation results.
To choose an optimal weighting of censored data in practice, one could use an “optimization pro-
cedure” to minimize the total mean squared error  )
)


   ,   
+
2 . That is, one selects the value of #
that corresponds to the smallest value for the estimated sum of squared errors. Using this criterion, in
our simulations the weight of choice is # ﬀ in both configurations. Alternatively, one could minimize
9
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other quantities such as the total coefficient of variation  
G*H

var 



>=



 , where  is the dimension
of    and


 is the  th component of

   .
4 4 2 Example: The CHS Study
The Cardiovascular Heath Study (CHS) is a population based observational prospective study of el-
derly adults (age 	 at enrollment) in the United States. A full description of the design of CHS is
reported in Fried et al (1991). The analysis here includes 3967 subjects (1531 males) between 65 and 95
years old who were free of clinical cardiovascular events at enrollment. There were 585 (14.7%) who
experienced a cardiovascular event during the study. Follow up on subjects without cardiovascular
events averaged 6.75 years (sd = 1.58 years). Here we consider the Framingham Risk Score (FR-score)
as a predictor for cardiovascular events. The FR-score is a widely used clinical prediction score used
to quantify risk for cardiovascular events (Grundy et al, 1998, 2001). It includes information on age,
cigarette smoking, blood pressure, diabetes mellitus, blood cholesterol and high density lipoproteins
cholesterol. Separate score sheets are used for men and women.
The FR-score was evaluated for all subjects at enrollment, and we only include this baseline as-
sessment in this analysis. Thus    for all observations. We considered gender and medication for
hypertension as covariates that might have a substantial influence on the predictive accuracy of the
FR-score. We fit the following models for the time dependent TPR and FPR functions:
TPR
#%$ 
  ,
	 )
"
H 0<&
"

0

&(' H H1&('



& -
+
( 2
FPR 6
$ 
ﬀ ,
	 ) H H&



& 3
+
( 2
where  H;  for subjects on medication for hypertension at enrollment and 0 otherwise, 

  for
males and 0 otherwise, and we drop the subscript ’s’ relative to the general model forms (3 4 1) and
(3 4 2) because   , the FR-score, is measured only at baseline,    . We choose 5ﬂ years in the
analysis. That is, we investigated the predictive accuracy of the FR-score for events during the  years
subsequent to enrollment. Subjects without an event by the 70- year of observation after the FR-score
is measured are considered to be controls for the purposes of calculating the false positive rate.
There is little loss to follow up in CHS. However, 487 subjects in the sample died from other causes
without a cardiovascular failure. Rather than censoring these survival times at death which would
imply that they were subsequently at risk for cardiovascular events, we censor them at the end of the
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trial. Since ;, ;* %0  represents the marginal probability of a cardiovascular events by time 0 , it is
appropriate to include them as definite non-events in the estimation of
;  %03
(Pepe and Mori, 1993).
The estimated regression coefficients and their estimated standard errors are shown in Table 1. The
estimated FPR and TPR functions for different groups at 0= year and 0   years are shown in Figure
1 and their corresponding ROC curves are presented in Figure 2. The lack of a gender effect on the FPR
functions ( 

  ) indicate that in order to control the FPR at a particular value, the same threshold
value  can be used for males and females. The positive value of '

indicates however that for a given
threshold value, the FR-score appears to have higher sensitivity in females than in males for detecting
subsequent cardiovascular events but similar specificity. The estimated FPR and TPR functions shown
in Figure 1 illustrate this. Medication use appears to be associated with higher false positive and true
positive rates since both coefficient estimates  H and ' H are negative. The medication effect on the TPR
is less than that on the FPR. This translates into the ROC curve for those on medication being less than
for those who are not on medication, as illustrated in Figure 2. In other words, the FR-score is better at
distinguishing between subjects who will and will not have a cardiovascular event when they are not
on medication. We have noted that given the same false positive rate, the corresponding true positive
rate is substantially higher in females than in males. As shown in Table 2, the area under the ROC
curve (AUC) in females is about     (sd =   

) higher than that in males in both medication groups
at year 1. The gender effect is statistically significant. However, the medication effect is not. The AUC
in subjects on medication is only about   

(sd =   

) lower than that in subjects not on medication
(for both male and female) at year 1.
Perhaps the most important and disappointing result of our analysis however is that the FR-score
is a very inaccurate marker for cardiovascular events. The ROC curves in Figure 2 demonstrate that
the benefit of a high TPR can only be achieved at the expense of an accompanying high FPR and vice
versa. It does not have adequate sensitivity and specificity (at any threshold) for accurate individual
level prediction of cardiovascular events. Figure 3 displays the estimated TPR functions for events at
at 0   year and  years after the FR-score is measured in male subjects who are not on hypertension
medication. These curves indicate that for any positivity threshold  , the sensitivity of the FR-score is
higher for events that occur at 1 year after enrollment than at  years after enrollment. In particular for
these men, the threshold criterion FR-score : ' which identifies 45% of subjects with events at  year
after enrollment, identifies only 36% of subjects with events at  years. The FPR functions for those
11
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still without events at  years after enrollment is also shown in Figure 3. Of those subjects, 30% also
meet criterion that FPR-score : ' .
We next calculate the cumulative incidence based TPR and FPR functions defined in section 1 and
derive the area under the corresponding ROC curves. Estimators for TPRCI
#%$ &$ 
 4  and FPRCI
#%$ &$ 
 4  can be
derived from our proposed models in (3 4 1) and (3 4 2) noting the following identities:
TPRCI
#%$ &$ 
 
, 6
#
+
ﬂ D
! #"" " $
  3 ﬁ&4''' ) +  & -
+
(
.
9 ;   & "
 , ;  %0<& 

FPRCI
#%$ &$ 
 
,76
6
#
ﬂ D
  #"" "$
  3"ﬁ&('''
) +
 & -
+
(
.
9ﬀ;    &   & ﬂ /D )
	 $
!" &
0
)
+
 &(3 2 ;  5 & "
;  %0<& 

The definitions of the cumulative incidence based TPR and FPR functions specify cases and controls
at time 0 as subjects with ﬃ 0 and subjects with ﬃ :0 , respectively. The results are presented in
Figure 4 and Table 3. At any given positivity threshold, both the true and false positive rates of the
FR-score are higher for 0   year since enrollment than for 0   years since enrollment. The FR-
score is better at distinguishing subjects who fail within 1 year from those do not than distinguishing
subjects who fail within  years from those do not. In particular, for female subjects who are on hy-
pertension medication, the AUC for the cumulative incidence ROC curve is   

(sd=   

) when 0=
year and is     (sd=   

) when 0   years. Comparing the AUC between  year and  years for
this subgroup, we have a difference of     with standard error   

. Shown also in Figure 4 are the
non-parametric estimates (Heagerty et al, 2000) of the ROC curves using data from each subgroup.
The nonparametric estimates are reasonably close to the model based estimates suggesting that the
assumed semi-parametric models are reasonable.
5 REMARKS
Statistical models for the joint analysis of longitudinal biomarkers and time to disease onset have been
studied extensively in the past decade (e.g., Pawitan and Self, 1993; De Gruttola and Tu, 1994; Tsiatis,
De Gruttola and Wulfsohn, 1995; Faucett and Thoams, 1996; Wulfsohn and Tsiatis 1997; Hogan and
Laird, 1997; Hederson, Diggle and Dobson, 2000; Skates, Pauler and Jacobs, 2001; Wang and Taylor,
2001; Henderson, Diggle and Dobson, 2002). See Hogan and Laird (1997) for discussion of two broad
classes of models, namely selection models and pattern mixture models. Most of the existing methods
in this area require parametric modeling of the marker process over time and a joint parametric model
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for the distribution of the event time. To induce models for the association between the marker and
event time process, both mixture models and selection models rely on specification of distributional
assumptions for random effects or latent stochastic processes. In contrast, we use marginal semi-
parametric models for the marker distribution given the event time and for the event time distribution.
The approach does not model marker processes and hence is more flexible. We estimate the regression
parameters and the non-parametric baseline functions simultaneously based on estimating equations
and incorporate censoring by integrating over time.
There are several directions in which the methodology proposed here should be enhanced. First,
procedures to assess model fit and to assist in model selection need development. Although the models
are semiparametric, there is an assumption that covariate effects are additive on the scale of the link
function and we did not test the adequacy of this assumption in our data analysis. Second, we have
restricted to time independent covariates. It would be of interest to generalize the models to include
time varying covariates. This is straightforward if covariates are external but more complicated when
covariates are internal in the sense defined by Kalbfleisch and Prentice (2002). Third, we have restricted
to biomarkers measured prior to the occurrence of the event. However in some applications, such as in
infectious disease research, there would be interest in using the biomarker to detect the event as soon
as possible after ﬃ . Fourth, we do not allow censoring of ﬃ to depend on the marker   conditional on
the covariates. To do so would induce bias into the estimated true and false positive rates, commonly
referred to as ’verification bias’ in the diagnostic testing literature (Begg and Greenes, 1983). Studies
that seek to evaluate the sensitivity and specificity of a marker should be designed so that follow up
does not depend on the marker. However, extensions that relax this requirement somewhat could
be possibly developed using inverse probability weighting for example (Robins et al, 1995). Finally,
our methods can be used to assess the relative performance of two markers. One would fit separate
models for each of the markers and plot the induced ROC curves. Comparisons could then be made
using AUC statistics for example. It would be interesting to explore this further with real data.
ACKNOWLEDGEMENT
The authors are grateful to reviewers for constructive comments that lead to substantial improve-
ment to the paper. Support for this research was provided by NIH grants GM-54438 and AI29168.
Participating Institutions and Principal Investigators for CHS are: Wake Forest University School of
13
Hosted by The Berkeley Electronic Press
Medicine: Gregory L. Burke MD. Wake Forest University-ECG Reading Center: Pentti M. Rautaharju
MD PhD. University of California, Davis: John Robbins MD MHS. The Johns Hopkins University:
Linda P. Fried MD MPH. The Johns Hopkins University-MRI Reading Center: Nick Bryan MD PhD,
Norman J. Beauchamp MD. University of Pittsburgh: Lewis H. Kuller, MD DrPH. University of Cali-
fornia, Irvine-Echocardiography Reading Center (baseline): Julius M. Gardin MD. Georgetown Medi-
cal Center-Echocardiography Reading Center (follow-up): John S. Gottdiener MD. New England Med-
ical Center, Boston-Ultrasound Reading Center: Daniel H. O’Leary MD. University of Vermont-Central
Blood Analysis Laboratory: Russell P. Tracy PhD. University of Arizona, Tucson-Pulmonary Reading
Center: Paul Enright MD. Retinal Reading Center-University of Wisconson: Ronald Klein MD. Univer-
sity of Washington-Coordinating Center: Richard A. Kronmal PhD. NHLBI Project Office: Jean Olson
MD MPH. The CHS research was supported by contracts N01-HC-85079 through N01-HC-85086, N01-
HC-35129, and N01-HC-15103 from the National Heart, Lung, and Blood Institute.
14
http://biostats.bepress.com/harvardbiostat/paper23
APPENDIX
A UNIQUENESS AND CONSISTENCY
We first show that  C C C is a consistent estimate of C C C + for  

  . To this end, let

  - 
   
 
3"    ﬁ
)
denote
the solution to (3 4 3) at a given    and
 
  C C C 

2

G*H



  G*H


(    	(    
 C C C ﬁ&-)  , 
(    	( 2 )  ,    
 C C C  2
	 
It is easy to see that   -        argmax 
ﬀﬁﬀ
ﬂ
 
  C C C  ,
 
3      argmax 
ﬀ/ﬀ
ﬂ
 
  C C C  and       argmax
  
 

     ,
where
 

    6
'
)
 
*(    -  4    
 
3  4        + 9

,
( . Suppose    + lies in a compact set 
.
. To show that      , the
maximizer of
 

     is strongly consistent, it is sufficient to show that
 

     converges uniformly to a
deterministic function of    almost surely, which has a unique minimizer at    + (Newey and McFadden,
1994). To this end, let 8 4  denote the distribution function of  ﬂ) 
(  5<	7   5<3"  2 ,   - (
  - 

     and
 
3 (9
 
3 

      . It follows from strong law of large numbers that  N H 6
'
)
 


C C C 
9

,
(
6
'
)


C C C 
9
,
 , where



C C C 
+
&

HH


C C CJ+**
HH


C C C  &-) ,M
HH


C C C +7 2 )  ,M
HH


C C C  2
9
8
HH

and  +  Eﬀ
8

N H 
E
 G*H


	
 
. Since ﬁ     + (  ﬁ&   ,M + <  ,   has a unique maximizer
 ﬃ
+ for any  +     , we have    C C C  	    C C C + and the equality holds if and only if  HH   C C C  
ﬁHH7

C C C
+
 , for  ﬃﬂ  )* 

  !
9
,
(>=
9
.:ﬂ2 and  HH "ﬃ# where $# is the domain of  HH . It
follows from the monotonicity of ﬂ D  4  and ﬂ /D  4  that
- (<& ' ' '
)
 &
 #" " "
% 3" -
+
(ﬁ&('''
) +
 &
 #"" "
$
% 3  (A.1)
3(ﬁ&
0
)
 &
	
!"'&
+
(ﬁ&
0
)+
 &
	
$
!" (A.2)
for  (ﬂ  and any % 3    in the subspace of  # restricting to )   . Without loss of generality,
we assume that  # is not degenerate. It follows that (A.1) and (A.2) holds if and only if   -    + ,
- (  -
+
( , and 3(  3 + ( for  ﬃﬂ  . This ensures that the limit of
 

     , denoted by      , has a
unique minimizer at    % + . It is not hard to show that that
 

    is equicontinuous in    , therefore the
convergence of
 

   *

     is uniform in   +
.
. This concludes the arguments for consistency of      .
The equicontinuity of
 


  
+
 in -  and 3( ensures the consistency of   - ( and
 
3( . The consistency
of   -  4  and
 
3  4  is uniform in  

   since -  4  and 3 4  are monotone functions of  .
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It remains to show the consistency of

C C C . Let

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
	
 
,  

  
 
be  ,

	
 
,

  
 
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; ﬀ  4 
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; ﬀ  4 
, respectively. Let
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Let

	
  C C C  and

     denote the left hand side of (A.3) and (A.4), respectively. It follows from the
strong law of large numbers and the uniform consistency of

; 
 4  that for any  	  ,  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where C C C
  )

 4 

  2 . This, coupled with the monotonicity and continuity of ﬂ and ﬂ /D, im-
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. When )   and    are non-degenerate,  is positive definite. Now,
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
   
+
   , by the standard inverse function theorem, there exists a unique solution
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the equation
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Table 1: Estimated regression coefficients and their estimated standard errors for the TPR and FPR
models of the Framingham Risk Score as a predictor for cardiovascular events within 7 years.
"
H
"

' H '

 H 

Estimate 0.190 -0.021 - 0.275 0.318 -0.390 0.012
# ﬀ Std. Error 0.078 0.011 0.086 0.087 0.037 0.033
Estimate 0.190 -0.021 -0.274 0.317 -0.388 0.019
#   Std. Error 0.078 0.011 0.086 0.087 0.039 0.035
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Table 2: Estimated AUCs and their standard errors. Shown also are the differences in AUCs between groups and between years.
 
Year,
 
Gender and
 
Med denote the difference in AUC between Year 1 and Year 5, between Female and Male, and between No
medication and with medication, respectively.
Year 1 Year 5
 
Year
Female Male
 
Gender Female Male
 
Gender Female Male
No Med. 
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Table 3: Estimated AUCs for the cumulative incidence based ROC curves and their standard errors. Shown also are the differ-
ences in AUCs between groups and between years.
 
Year,
 
Gender and
 
Med denote the difference in AUC between Year 1 and Year
5, between Female and Male, and between No medication and with medication, respectively.
Year 1 Year 5
 
Year
Female Male
 
Gender Female Male
 
Gender Female Male
No Med. 
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Figure 1: Estimated TPR / FPR functions of the Framingham risk score for all 4 groups: female sub-
jects (solid curves) / male subjects (dashed curves) who are on medication (thicker curves) / not on
medication (thinner curves).
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Figure 2: Plots of the ROC curve: the TPR function vs the FPR function at 0  year and 0   years.
Shown are plots for females (solid curves) and for males (dashed curves). Thicker curves are for those
on medication and thiner curves are for those not on medication.
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Figure 3: Estimated TPR / FPR functions of the Framingham risk score for male subjects who are not
on medication. The sensitivities (TPR) for events at 0= and 0= years after the FR-score is measured
are displayed. Shown also are their 95% simultaneous confidence bands (shaded regions).
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Figure 4: Plots of the cumulative incidence based ROC curve: at 0= year and 0= years. Shown are
the semi-parametric model based estimates (solid curves) and the non-parametric estimates (Heagerty
et al, 2000) (dashed curves).
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